Socioeconomic disparities in the prevalence of comorbid chronic conditions among Canadian adults with cancer

Abstract Objective To evaluate the prevalence of comorbid chronic conditions among Canadian adults with cancer and the impact of socioeconomic background on the distribution of these conditions. Methods Canadian Community Health Survey (CCHS) 2017–2018 dataset was accessed and individuals with complete information about cancer history were reviewed. The prevalence of the following 10 chronic conditions was reviewed: asthma, chronic obstructive pulmonary disease, arthritis, hypertension, hypercholesterolemia/hyperlipidemia, heart disease, stroke, diabetes, mood disorder, and anxiety disorder. Stratification of the prevalence was done according to age, sex, and racial subgroups. Multivariable logistic regression analysis was done to evaluate the association between sociodemographic characteristics and having multiple comorbid conditions. Results A total of 104,362 participants were included in the current study (including 10,782 participants with a history of cancer; and 93,580 participants without a history of cancer). Among all age, sex, and race strata, participants with a history of cancer were more likely to have multiple chronic conditions (p < 0.05 for all comparisons). The most common three individual comorbid conditions among participants with cancer were arthritis (40.2%), hypertension (36.1%), and hypercholesterolemia (25.2%); while the most common cancer-comorbidity triad among participants with cancer was cancer/arthritis/hypertension (17.7%). In a multivariable logistic regression analysis among participants with cancer, the following sociodemographic factors were associated with having multiple comorbid conditions: older age (OR for age 80+ versus age 18–20 years: 8.32; 95% CI: 5.17–13.39), indigenous racial group (OR: 1.94; 95% CI: 1.43–2.63) and lower income (OR for income ≥80,000 Canadian dollars (CAD) versus income: ≤20,000 CAD: 0.29; 95% CI: 0.23–0.37). Conclusion History of cancer is associated with a higher probability of many comorbid conditions. This excess comorbidity burden seems to be unequally shouldered by individuals in the lower socioeconomic stratum as well as minority populations.

[1]  O. Abdel-Rahman Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  O. Abdel-Rahman Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer. , 2020, Journal of comparative effectiveness research.

[3]  K. Mulder,et al.  Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer , 2020, International Journal of Colorectal Disease.

[4]  Sharon M. Watanabe,et al.  Burden of depression among Canadian adults with cancer; results from a national survey , 2020, Expert review of pharmacoeconomics & outcomes research.

[5]  O. Abdel-Rahman Patient-reported Cognitive and Functional Impairments Among Older Canadians With Cancer; A Population-Based Study. , 2020, Journal of pain and symptom management.

[6]  D. Brenner,et al.  Projected estimates of cancer in Canada in 2020 , 2020, Canadian Medical Association Journal.

[7]  L. Pickering,et al.  Are health-care policies restricting further progress in cancer survival outcomes? , 2019, The Lancet. Oncology.

[8]  A. Gavin,et al.  Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. , 2019, The Lancet. Oncology.

[9]  J. de Boniface,et al.  Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer , 2019, Breast Cancer Research and Treatment.

[10]  C. Friedenreich,et al.  The future burden of cancer in Canada: Long-term cancer incidence projections 2013-2042. , 2019, Cancer epidemiology.

[11]  I. Pabinger,et al.  Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  O. Abdel-Rahman Impact of Diabetes on the Outcomes of Patients With Castration‐resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies , 2019, Clinical genitourinary cancer.

[13]  Min Hu,et al.  Socioeconomic inequalities in health among Indigenous peoples living off-reserve in Canada: Trends and determinants. , 2018, Health policy.

[14]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  J. Goodwin,et al.  Adapting the Elixhauser comorbidity index for cancer patients , 2018, Cancer.

[16]  J. Spinelli,et al.  Cancer in First Nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010 , 2017, Cancer Causes & Control.

[17]  A. Deal,et al.  Patient-Reported Comorbidity and Survival in Older Adults with Cancer. , 2018, The oncologist.

[18]  Sarah E. Nelson,et al.  The mental health of Indigenous peoples in Canada: A critical review of research. , 2017, Social science & medicine.

[19]  D. Sarfati,et al.  The impact of comorbidity on cancer and its treatment , 2016, CA: a cancer journal for clinicians.

[20]  Y. Fouad,et al.  Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments , 2016, Expert opinion on drug safety.

[21]  Robert G Uzzo,et al.  Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work , 2015, Medical care.

[22]  D. Withrow,et al.  Cancer survival among First Nations people of Ontario, Canada (1968–2007) , 2014, International journal of cancer.

[23]  Brian W. Ward,et al.  Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From the National Health Interview Survey, 2010 , 2013, Preventing chronic disease.

[24]  S. Pohar,et al.  A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer , 2006, Health and quality of life outcomes.

[25]  M. Gould,et al.  Understanding Comorbidity Profiles and Their Effect on Treatment and Survival in Patients With Colorectal Cancer. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  L. Mery,et al.  Cancer incidence in Canada: trends and projections (1983-2032). , 2015, Health promotion and chronic disease prevention in Canada : research, policy and practice.

[27]  T. Choueiri,et al.  Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.